Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Gordon James who wrote (490)	8/24/1999 10:01:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 717

Thanks, Gordon - I hadn't seen the Bloomberg release. I was encouraged by just how quickly this Phase I trial was enrolled and completed - this is sometimes a good proxy for how promising the treatment is. My instinct is that this is eventually going to be a successful treatment. The initial results were respectable: Using IVUS, it was reported that 12 of 14 evaluable patients responded to treatment, defined as an increase of greater than 10% in the blood vessel opening or minimal luminal diameter (MLD). Responding patients had increases in MLD up to 76% with a mean of 35%. This is the sort of treatment were there is lots of room for tweaking to get better performance. You get to juggle the drug dose, the light dose, the time before light exposure as well as repeated procedures. The down side of this juggling of course is that the Phase II trials are more complex. Peter